Advertisement

Topics

VenatoRx secures $9.4m to develop new class of antibiotic fro multi-drug resistant bacteria

19:00 EDT 26 Jul 2017 | Pharmaceutical Business Review

VenatoRx Pharmaceuticals, which focuses on discovery and development of novel therapies for highly drug resistant bacterial infections, has been awarded up to $9.4m from CARB-X (Combating Antibiotic-Resistant Bacteria Accelerator).

Original Article: VenatoRx secures $9.4m to develop new class of antibiotic fro multi-drug resistant bacteria

NEXT ARTICLE

More From BioPortfolio on "VenatoRx secures $9.4m to develop new class of antibiotic fro multi-drug resistant bacteria"

Quick Search
Advertisement
 

Relevant Topic

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...